Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Ropinirole Prolonged-Release Delivery System Reduces Off Time and Improves Motor Symptoms in Advanced Parkinson's Disease: Presented at ANA By Maggie Schwarz WASHINGTON, DC -- October 11, 2007 -- In a trial of patients with advanced Parkinson's disease who were not optimally controlled with levodopa, prolonged-release ropinirole significantly reduced off time, and improved motor symptoms, according to research presented here at the 132nd Annual Meeting of the American Neurological Association (ANA). Researchers enrolled patients with Parkinson's disease who were not controlled optimally with levodopa and randomised 202 patients to adjunctive treatment with prolonged-release ropinirole and 191 to placebo. Treatment was administered once daily for 24 weeks. Lead author Rajesh Pahwa, MD, Director, Parkinson's Disease and Movement Disorder Center, and Laverne and Joyce Rider Professor of Neurology, University of Kansas School of Medicine, Kansas City, Kansas, United States, presented the study results in a poster session on. The initial dose of ropinirole was 2.0 mg daily and was titrated to a maximum of 24.0 mg daily. At 8.0 mg daily and at each subsequent increase, levodopa dose reduction was required. The primary endpoint was a mean change in daily off time at week 24 (last observation carried forward [LOCF]). Post hoc analyses assessed mean changes from baseline in tremor, rigidity, and bradykinesia components of the Unified Parkinson's Disease Rating Scale (UPDRS) at week 24 LOCF. Prolonged-release ropinirole reduced daily off time significantly compared with placebo at week 24 LOCF (P <.0001). At week 24 LOCF, significantly greater improvements were seen with ropinirole 24-hour compared with placebo, for changes in tremor (P =.0001), rigidity (P =.0003) and bradykinesia (P <.0001) from baseline. Mean dose of ropinirole at the last assessment was 18.8 mg +- 6.3 mg daily. Dr. Pahwa concluded that the dopamine agonist ropinirole, in a prolonged-release formulation, can improve difficult-to-control symptoms of advanced Parkinson's disease, a stage of the disease notable for suboptimal control using levodopa. [Presentation title: Adjunctive Ropinirole 24-Hour Prolonged Release Reduced "Off" Time and Improves the Cardinal Symptoms of Tremor, Rigidity, and Bradykinesia in Patients With Advanced Parkinson's Disease (PD). Poster 2] E-mail this page to a friend or colleague! To print, use this version